Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information

INTRODUCTION: Clinical trials in Alzheimer's disease are aimed at early stages of disease, including preclinical Alzheimer's disease. The high cost and time required to screen large numbers of participants for Aβ pathology impede the development of novel drugs. This study's objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Insel, Philip S., Palmqvist, Sebastian, Mackin, R. Scott, Nosheny, Rachel L., Hansson, Oskar, Weiner, Michael W., Mattsson, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Cognitive & Behavioral Assessment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045949/
https://www.ncbi.nlm.nih.gov/pubmed/27722193
http://dx.doi.org/10.1016/j.dadm.2016.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045949/
https://www.ncbi.nlm.nih.gov/pubmed/27722193
http://dx.doi.org/10.1016/j.dadm.2016.07.002

Ejemplares similares